|
業務類別
|
Biotechnology |
|
業務概覽
|
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without addingburden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment. |
| 公司地址
| 60 Rue de Wattignies, Paris, FRA, 75012 |
| 電話號碼
| +33 140260470 |
| 傳真號碼
| +33 140260444 |
| 公司網頁
| https://www.nanobiotix.com |
| 員工數量
| 97 |
| Dr. Laurent Levy, PhD |
Chairman of the Executive Board and Principal Executive Officer |
歐元 460.00K |
31/03/2026 |
| Ms. Anne-Juliette Hermant |
Chief People Officer and Member of the Executive Board |
歐元 260.00K |
31/03/2026 |
| Dr. Louis Kayitalire, M.D. |
Chief Medical Officer and Member of the Executive Board |
歐元 415.00K |
31/03/2026 |
| Mr. Bart Van Rhijn |
Chief Financial and Business Officer and Member of the Executive Board |
歐元 420.48K |
31/03/2026 |
|
|
| Ms. Anat Naschitz |
Member of the Supervisory Board |
31/03/2026 |
| Mr. Enno Spillner |
Member of the Supervisory Board |
31/03/2026 |
| Ms. Anne-Marie Graffin |
Vice Chairman of the Supervisory Board |
31/03/2026 |
| Dr. Alain Herrera, M.D.,PhD |
Member of the Supervisory Board |
31/03/2026 |
| Dr. Margaret A. Liu, M.D. |
Member of the Supervisory Board |
31/03/2026 |
| Dr. Gary M. Phillips, M.D. |
Chairman of the Supervisory Board |
31/03/2026 |
|
|
|
|
